跳至主要内容
临床试验/NCT04886934
NCT04886934Enrolling By Invitation不适用

Open Clinical Investigation to Assess Performance of a Temporary Epicardial Pace Wire With Integrated Sensor for Continuous Postoperative Monitoring of Myocardial Function After Heart Surgery Compared to Ultrasound

Cardiaccs AS2 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2021年10月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
Cardiaccs AS
入组人数
38
试验地点
2
主要终点
Change from Baseline Peak Systolic Velocity (PSV) after increasing heart rate by 25 percent

研究概览

简要总结

Transesophageal echocardiography is used to monitor cardiac wall motion at various time points during open-heart surgery. After surgery, the measurements are made at various time points by transthoracic echocardiography.

The CS1 system enables continuous, direct measurement of cardiac wall motion. This is achieved through use of temporary pacemaker wires incorporating a motion detector called an accelerometer. Use of TMEs during and after open-heart surgery is part of the normal clinical routine. Continuous monitoring of cardiac wall motion during and after surgery can quickly highlight the need for medical intervention with cardiac drugs and allow very early detection of potentially serious complications leading to abnormal cardiac wall motion.

Cardiac wall motion activity registered by the CS1 system and echocardiography at specific time points during and after surgery will be analyzed to see how well they compare.

详细描述

Echocardiography is currently the most important and most widely used tool in cardiology besides electrocardiography (ECG). It is reliable for assessing all stages of cardiovascular disease, and it is commonly used to detect heart (cardiac) wall motion dysfunction during and after open-heart surgery.

During open-heart surgery, transesophageal echocardiography (when the echocardiography sensor is introduced into the esophagus) is used to monitor cardiac wall motion at various time points during surgery. After surgery, the measurements are made at various time points by transthoracic echocardiography (when the echocardiography sensor is placed on the chest wall).

Use of the CS1 system enables continuous, direct measurements of cardiac wall motion. This is achieved through use of temporary pacemaker wires (also called temporary myocardial electrodes or TMEs) incorporating a motion detector called an accelerometer. Use of TMEs during and after open-heart surgery is part of the normal clinical routine. Continuous monitoring of cardiac wall motion during the surgery and the post-surgical recovery period can, for example, quickly highlight the need for medical intervention with cardiac drugs and allow very early detection of potentially serious complications such as ischemia (heart muscle is not receiving enough oxygen) and myocardial dysfunction (cardiac wall motion appears abnormal).

The key feature of the CS1 system is that the cardiac wall motion activity registered by the novel TMEs incorporating the accelerometer are displayed visually on a standard medical monitor and synchronized with the patient's ECG data. These data can easily be viewed by medical staff to check if the patient's condition is satisfactory or whether medical intervention is needed.

In the study, the CS1 system will be used in addition to the standard monitoring procedures that include ECG, blood pressures and intermittent echocardiography. Cardiac wall motion activity registered by the CS1 system and echocardiography at specific time points during and after surgery will be analyzed to see how well they compare.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
19 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with heart disease requiring surgery
  • Above 18 years
  • Patients suitable for study participation without safety concerns based on the Investigator's evaluation of medical history and physical examination.
  • The patient must be able to understand the aims and objectives of the trial, willing and able to comply with all study related procedures
  • The patient must be willing and able to provide written informed consent prior to participation in the clinical investigation
  • The patient agrees to abstain from enrollment in any other clinical investigation for the duration of the study

排除标准

  • Esophageal disease
  • Atrial fibrillation

研究组 & 干预措施

Safety and clinical performance of the CS1 system

Experimental

Placement of the CS1 device on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery.

干预措施: CS1 System (Device)

结局指标

主要结局

Change from Baseline Peak Systolic Velocity (PSV) after increasing heart rate by 25 percent

时间窗: After surgery: before extubation, while patient is in the intensive care unit (ICU)

Correlation between relative changes in PSVs measured by CS1 and echocardiography

Change from Baseline PSV after increasing heart rate by 25 percent

时间窗: After surgery: after extubation and removal of drains, before patient is transferred from ICU to general ward

Correlation between relative changes in PSVs measured by CS1 and echocardiography

次要结局

  • Adverse Events(Up to 30 days after surgery)
  • Adverse Device Effects(Up to removal of device at a maximum of 7 days after surgery)
  • Device Deficiencies(Up to removal of device at a maximum of 7 days after surgery)

研究者

发起方
Cardiaccs AS
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验